Patents by Inventor Shari Lynn CAPLAN
Shari Lynn CAPLAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240261372Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: February 7, 2024Publication date: August 8, 2024Inventors: BRIAN R. BOETTCHER, SHARI LYNN CAPLAN, DOUGLAS S. DANIELS, NORIO HAMAMATSU, STUART LICHT, STEPHEN CRAIG WELDON
-
Patent number: 11944664Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: GrantFiled: August 24, 2021Date of Patent: April 2, 2024Assignee: Novartis AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Patent number: 11802152Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.Type: GrantFiled: December 1, 2021Date of Patent: October 31, 2023Assignee: Novartis AGInventors: Brian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
-
Patent number: 11377656Abstract: This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.Type: GrantFiled: March 8, 2017Date of Patent: July 5, 2022Assignee: Novartis AGInventors: Shari Lynn Caplan, Katsumasa Nakajima
-
Publication number: 20220162300Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.Type: ApplicationFiled: December 1, 2021Publication date: May 26, 2022Inventors: Brian BOETTCHER, Shari Lynn CAPLAN, Regis CEBE, Guochun LI, John A. TARASZKA, Fangmin XU, David Langdon YOWE
-
Patent number: 11236159Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.Type: GrantFiled: August 2, 2016Date of Patent: February 1, 2022Assignee: Novartis AGInventors: Brian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
-
Publication number: 20210386824Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: August 24, 2021Publication date: December 16, 2021Applicant: Novartis AGInventors: BRIAN R. BOETTCHER, SHARI LYNN CAPLAN, DOUGLAS S. DANIELS, NORIO HAMAMATSU, STUART LICHT, STEPHEN CRAIG WELDON
-
Patent number: 11129874Abstract: The invention relates to nucleic acids encoding fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are vectors and host cells comprising the same and methods of producing the fusion proteins.Type: GrantFiled: August 30, 2018Date of Patent: September 28, 2021Assignee: Novartis AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Patent number: 10669323Abstract: The present invention relates to the identification of dual function fusion proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating metabolic, cardiovascular, and endocrine conditions related to glucose and/or lipid homeostasis.Type: GrantFiled: August 26, 2016Date of Patent: June 2, 2020Assignee: NOVARTIS AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Susan E. Cellitti, Douglas S. Daniels, Norio Hamamatsu, Bernhard Hubert Geierstanger, Stuart Licht, Andreas Loew, Stephen Craig Weldon
-
Publication number: 20200087392Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.Type: ApplicationFiled: August 2, 2016Publication date: March 19, 2020Inventors: Brian BOETTCHER, Shari Lynn CAPLAN, Regis CEBE, Guochun LI, John A TARASZKA, Fangmin XU, David Langdon YOWE
-
Publication number: 20190100752Abstract: This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.Type: ApplicationFiled: March 8, 2017Publication date: April 4, 2019Inventors: Shari Lynn CAPLAN, Katsumasa NAKAJIMA
-
Publication number: 20180369332Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: August 30, 2018Publication date: December 27, 2018Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Patent number: 10076554Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: GrantFiled: January 4, 2016Date of Patent: September 18, 2018Assignee: Novartis AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Publication number: 20170166621Abstract: The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.Type: ApplicationFiled: August 26, 2016Publication date: June 15, 2017Applicant: NOVARTIS AGInventors: Brian R. BOETTCHER, Shari Lynn CAPLAN, Susan E. CELLITTI, Douglas S. DANIELS, Norio HAMAMATSU, Bernhard Hubert GEIERSTANGER, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
-
Publication number: 20160367638Abstract: A formulation comprising a modified synthetic messenger RNA and a delivery agent. The modified synthetic messenger RNA encodes a leptin protein, is non-replicating and is translation-ready. The formulation can be delivered to a subject with congenital leptin deficiency, lipodystrophy or other condition where circulating leptin level is low.Type: ApplicationFiled: December 17, 2014Publication date: December 22, 2016Inventors: Crystal BYERS, Shari Lynn CAPLAN, Gabriel Grant GAMBER, Seung HAHM, Kurt Alex HELDWEIN, Igor SPLAWSKI, Thomas ZABAWA, Frédéric ZECRI
-
Publication number: 20160193297Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: January 4, 2016Publication date: July 7, 2016Applicant: NOVARTIS AGInventors: BRIAN R. BOELTCHER, SHARI LYNN CAPLAN, DOUGLAS S. DANIELS, NORIO HAMAMATSU, STUART LICHT, STEPHEN CRAIG WELDON
-
Publication number: 20160166634Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: February 25, 2016Publication date: June 16, 2016Applicant: NOVARTIS AGInventors: Shari Lynn CAPLAN, Andrei GOLOSOV, Philipp GROSCHE, Carla GUIMARAES, Aaron KANTER, Changgang LOU, David Thomas PARKER, Eric C. Peters, Aimee Richardson USERA, Kayo YASOSHIMA, Jun YUAN, Federic ZECRI, Hongjuan ZHAO
-
Patent number: 9340582Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.Type: GrantFiled: July 21, 2014Date of Patent: May 17, 2016Assignee: NOVARTIS AGInventors: Jun Yuan, Frederic Zecri, Philipp Grosche, Hongjuan Zhao, Eric Peters, Shari Lynn Caplan, Changgang Lou
-
Publication number: 20150030594Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Jun YUAN, Frederic ZECRI, Philipp GROSCHE, Hongjuan ZHAO, Andrei GOLOSOV, Kayo YASOSHIMA, David Thomas PARKER, Eric PETERS, Aimee Richardson USERA, Shari Lynn CAPLAN, Aaron KANTER, Changgang LOU, Carla Guimaraes